Sichuan Kelun Pharmaceutical Co.,Ltd.(002422),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

002422 Sichuan Kelun Pharmaceutical Co.,Ltd.

Closed 04-18 15:00:00

33.93

-0.25

-0.73%

High34.73	Low33.70	Vol8.44M
Open34.17	D1 Closing34.18	Amplitude3.01%
Mkt Cap54.22B	Tradable Cap44.31B	Total Shares1.60B
T/O287.00M	T/O Rate0.65%	Tradable Shares1.31B
P/B2.42	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"Sichuan Kelun Pharmaceutical Co.,Ltd.","latestPrice":33.93,"timestamp":1744959798000,"preClose":34.18,"halted":0,"volume":8437592,"delay":0,"changeRate":-0.0073,"floatShares":1306000000,"shares":1598000000,"eps":1.8546,"marketStatus":"Closed","change":-0.25,"latestTime":"04-18 15:00:00","open":34.17,"high":34.73,"low":33.7,"amount":287000000,"amplitude":0.0301,"askPrice":33.93,"askSize":21,"bidPrice":33.92,"bidSize":330,"shortable":0,"etf":0,"ttmEps":1.8546,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745199000000},"marketStatusCode":5,"adr":0,"adjPreClose":34.18,"symbolType":"stock","openAndCloseTimeList":[[1744939800000,1744947000000],[1744952400000,1744959600000]],"highLimit":37.6,"lowLimit":30.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.42,"roa":"--","peRate":18.29505,"roe":"11.32%","epsLYR":1.69,"committee":0.189369,"marketValue":54222000000,"turnoverRate":0.0065,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-04-22.","floatMarketCap":44308000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"2522681867","title":"Kelun Pharma's Subsidiary Gets Nod to Trial Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522681867","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522681867?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 11:57","pubTimestamp":1742961435,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical's  subsidiary, Sichuan Kelun Botai Biopharmaceutical, received the Chinese drug administration's approval to conduct clinical trials on the drug SKB107, according to a Shenzhen Stock Exchange filing on Wednesday.The drug was developed with the Affiliated Hospital of Southwest Medical University in Sichuan Province, China, to treat advanced solid tumors with bone metastasis.The company's shares fell over 1% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","LU2148510915.USD","BK0060","002422","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2518319751","title":"Kelun Pharma's Unit Gets Nod for Antigen Drug's Second Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2518319751","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518319751?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 12:12","pubTimestamp":1741666327,"startTime":"0","endTime":"0","summary":"China's drug administrator approved adding a second indication for sac-TMT, the antibody-drug conjugate targeting human trophoblast surface antigen 2 of Sichuan Kelun Pharmaceutical's  unit, Sichuan Kelun Botai Biopharmaceutical, according to a Shenzhen Stock Exchange disclosure on Tuesday.The drug's second indication states that it can be used for treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer, the pharmaceutical company said.The drug is also used for breast cancer, gastric cancer, gynecological tumors and other advanced solid tumors.The company's shares rose 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064130708.USD","LU2148510915.USD","BK0239","BK0060","002422","LU1064131003.USD"],"gpt_icon":0},{"id":"2510074370","title":"Kelun Pharmaceutical Gets Chinese Drug Registration for Antibiotic","url":"https://stock-news.laohu8.com/highlight/detail?id=2510074370","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510074370?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 13:23","pubTimestamp":1739165020,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  obtained registration approval from China's drug administrator for its Imipenem-cilastatin sodium/sodium chloride injection.Combined with cilastatin sodium, carbapenem antibiotic imipenem can avoid inactivation by kidney metabolism and improve kidney safety, according to a Saturday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002422","BK0060","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0239"],"gpt_icon":0},{"id":"2510900761","title":"Kelun Pharmaceutical Gets Marketing Approval for Anti-cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2510900761","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510900761?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 13:17","pubTimestamp":1739164670,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  received marketing approval from China's medical products administrator for its cetuximab N01 injection.The drug is indicated for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX or FOLFIRI chemotherapy regimens, according to a Feb. 8 filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064130708.USD","BK0239","LU2148510915.USD","002422","BK0060","LU1064131003.USD"],"gpt_icon":0},{"id":"2505291604","title":"Sichuan Kelun Pharmaceutical Gets Marketing Approval for Carcinoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2505291604","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505291604?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 12:55","pubTimestamp":1737435330,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  subsidiary Sichuan Kelun Botai Biopharmaceutical obtained marketing approval from China's medical products administrator for its tagorizumab drug.The drug is a monoclonal antibody targeting programmed cell death ligand 1, according to a Tuesday filing with the Shenzhen bourse. It is used for treating recurrent or metastatic nasopharyngeal carcinoma.Shares of the company were down 2% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002422","LU1064130708.USD","BK0239","LU1064131003.USD","LU2148510915.USD","BK0060"],"gpt_icon":0},{"id":"2505299124","title":"Sichuan Kelun Pharmaceutical Gets Approval for Clinical Trials for Antitumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505299124","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505299124?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 12:36","pubTimestamp":1737434170,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  secured the approval of China's medical products administrator to conduct clinical trials for its SKB445 drug.SKB445 is intended to target advanced solid tumors, according to a Tuesday filing with the Shenzhen bourse.Shares of the company were down 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2148510915.USD","BK0060","LU1064131003.USD","LU1064130708.USD","BK0239","002422"],"gpt_icon":0},{"id":"2502905429","title":"Kelun Pharma Gets Nod for Luqubopa Tablets' Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2502905429","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502905429?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 13:00","pubTimestamp":1736398809,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  obtained drug registration approval from the Chinese drug administration for its drug, luqubopa tablets, according to a Shenzhen Stock Exchange disclosure on Thursday.The oral drug was used to treat thrombocytopenia in chronic liver disease and  reduce bleeding events, the pharmaceutical company said.The company's shares rose less than 2% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064130708.USD","BK0239","002422","LU1064131003.USD","LU2148510915.USD","BK0060"],"gpt_icon":0},{"id":"2501146791","title":"Sichuan Kelun Pharmaceutical Gets Acceptance for New Drug Application for Breast Cancer Drug; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501146791","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501146791?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 13:01","pubTimestamp":1736312483,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  subsidiary Sichuan Kelun Botai Biopharmaceutical received acceptance from China's medical products administrator for the new drug application of disitamab vedotin.Disitamab vedotin is intended to treat unresectable or metastatic breast cancer in adult patients, according to a Wednesday filing with the Shenzhen bourse.Shares of the pharmaceutical company declined 3% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064130708.USD","LU2148510915.USD","002422","LU1064131003.USD","BK0060","BK0239"],"gpt_icon":0},{"id":"2500300561","title":"Sichuan Kelun Pharmaceutical Gets Drug Registration Approval for Antihypertensive Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2500300561","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500300561?lang=en_us&edition=full_marsco","pubTime":"2025-01-03 12:18","pubTimestamp":1735877926,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical (SHE:002422) obtained drug registration approval from China's food and drug administrator for its clevidipine emulsion injection.Clevidipine is a fast-acting intravenous antihypertensive drug, according to a Friday fling with the Shenzhen bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064131003.USD","002422","LU1064130708.USD","LU2148510915.USD","BK0060","BK0239"],"gpt_icon":0},{"id":"2500991048","title":"Sichuan Kelun Pharmaceutical Unit Secures Approval for Tagolizumab Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2500991048","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500991048?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 13:52","pubTimestamp":1735797120,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical (SHE:002422) subsidiary Sichuan Kelun Biotech received approval from China's medical products administrator for the launch of Tagolizumab.Tagolizumab is a targeted humaniz","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","002422","BK0060","BK0239"],"gpt_icon":0},{"id":"2489343563","title":"Sichuan Kelun Pharmaceutical Gets China Clinical Trial Nod for Anti-Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2489343563","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489343563?lang=en_us&edition=full_marsco","pubTime":"2024-12-05 18:10","pubTimestamp":1733393406,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved Sichuan Kelun Pharmaceutical's (SHE:002422) clinical trial application for its SKB500 anti-tumor drug, according to a Thursday filing with the Shenzhen Stock Exchange.Shares closed 1% lower during Thursday's trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","002422","BK0239","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2487630541","title":"Sichuan Kelun Pharmaceutica  Says Five Company Products Include in China Drug Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2487630541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487630541?lang=en_us&edition=full_marsco","pubTime":"2024-11-29 11:59","pubTimestamp":1732852751,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nL3N3N009O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","LU1064131003.USD","BK0239","002422","LU1064130708.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2487305073","title":"BRIEF-Sichuan Kelun Says Five Products Include In China Drug Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2487305073","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487305073?lang=en_us&edition=full_marsco","pubTime":"2024-11-29 11:59","pubTimestamp":1732852751,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun Says Five Products Include In China Drug CatalogNov 29  - Sichuan Kelun Pharmaceutical Co Ltd 002422.SZ:SAYS FIVE COMPANY PRODUCTS INCLUDE IN CHINA DRUG CATALOGSource textFurther company coverage: 002422.SZ  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nL3N3N009O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","002422","BK0060","LU2148510915.USD","BK0239","LU1064131003.USD"],"gpt_icon":0},{"id":"2486015916","title":"Kelun Pharmaceutical's Unit Gets Nod to Trial Tumor Drug; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486015916","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486015916?lang=en_us&edition=full_marsco","pubTime":"2024-11-26 11:33","pubTimestamp":1732591989,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical's  unit, Sichuan Kelun Botai Biopharmaceutical, will conduct clinical trials on its drug, SKB501, after receiving approval from China's National Medical Products Administration, according to a Shenzhen Stock Exchange filing on Tuesday.Kelun Botai Biopha developed the antibody-drug conjugate or ADC drug as a treatment against advanced solid tumors, the pharmaceutical company said.The company's shares jumped less than 3% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064131003.USD","BK0060","002422","LU1064130708.USD","BK0239","LU2148510915.USD"],"gpt_icon":0},{"id":"2484969491","title":"Kelun Pharmaceutical's Unit Gets Nod to Trial Two Tumor Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2484969491","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484969491?lang=en_us&edition=full_marsco","pubTime":"2024-11-18 13:04","pubTimestamp":1731906241,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical's  unit, Sichuan Kelun Botai Biopharmaceutical, will conduct clinical trials on two drugs after obtaining approval from the Chinese drug administration, according to a Shenzhen Stock Exchange disclosure on Monday.The regulator approved the clinical trials of SKB571 and SKB535.The SKB571 has been developed as a treatment against tumors in cases, such as lung cancer and gastrointestinal tumors, while SKB535 was designed to treat advanced solid tumors, the pharmaceutical company said.The company's shares slipped more than 2% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","002422","BK0060","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","stockEarnings":[{"period":"1week","weight":-0.049},{"period":"1month","weight":0.072},{"period":"3month","weight":0.2352},{"period":"6month","weight":0.0491},{"period":"1year","weight":0.1822},{"period":"ytd","weight":0.1336}],"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","perCapita":"38691股","boardName":"医药制造业","registeredCapital":"159805万元","compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":-0.0437},{"period":"3month","weight":0.0108},{"period":"6month","weight":0.0047},{"period":"1year","weight":0.0659},{"period":"ytd","weight":-0.0224}],"survey":"　　四川科伦药业股份有限公司主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等25种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。主要产品涵盖麻醉镇痛、中枢神经、抗感染、肠外营养等领域。三年来，已实现41项仿制药连续获批上市，16个品种通过一致性评价，2个品种创新药物开展中美临床研究，新一代肿瘤免疫药物A293获批临床，首个创新药物A167完成关键II期临床疗效评估。公司作为国内医药创新和高质量发展的代表企业，荣获“中国制药集团研发20强”、“2019年中国医药研发产品线最佳工业企业”等荣誉称号。","serverTime":1745065599561,"listedPrice":83.36,"stockholders":"33751人(较上一季度增加7.70%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sichuan Kelun Pharmaceutical Co.,Ltd.(002422),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sichuan Kelun Pharmaceutical Co.,Ltd.(002422) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sichuan Kelun Pharmaceutical Co.,Ltd.,002422,Sichuan Kelun Pharmaceutical Co.,Ltd.股票,Sichuan Kelun Pharmaceutical Co.,Ltd.股票老虎,Sichuan Kelun Pharmaceutical Co.,Ltd.股票老虎国际,Sichuan Kelun Pharmaceutical Co.,Ltd.行情,Sichuan Kelun Pharmaceutical Co.,Ltd.股票行情,Sichuan Kelun Pharmaceutical Co.,Ltd.股价,Sichuan Kelun Pharmaceutical Co.,Ltd.股市,Sichuan Kelun Pharmaceutical Co.,Ltd.股票价格,Sichuan Kelun Pharmaceutical Co.,Ltd.股票交易,Sichuan Kelun Pharmaceutical Co.,Ltd.股票购买,Sichuan Kelun Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sichuan Kelun Pharmaceutical Co.,Ltd.(002422),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sichuan Kelun Pharmaceutical Co.,Ltd.(002422) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction